NCT06979609View on ClinicalTrials.gov

Secondary Prevention of Clostridioides Difficile Using Vancomycin

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2028

Study Completion Date

October 1, 2029

Conditions
Clostridioides Difficile InfectionClostridioides Difficile Infection RecurrenceClostridoides Difficile Associated Disease
Interventions
DRUG

Oral Vancomycin Prophylaxis

125mg PO BID for the duration of antibiotic re-exposure + 125mg PO QD for 7 days

DRUG

Placebo

2 capsules PO BID for the duration of antibiotic re-exposure + 1 capsule PO QD x 7 days

Trial Locations (1)

H4A3J1

RECRUITING

McGill University Health Centre, Montreal

All Listed Sponsors
lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT06979609 - Secondary Prevention of Clostridioides Difficile Using Vancomycin | Biotech Hunter | Biotech Hunter